Selected Cephalosporins & Penicillins/Probenecid Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Probenecid may decrease the ability of your kidneys to remove some antibiotics.

What might happen:

Levels of the antibiotic may be increased. This can be beneficial or necessary if you have a difficult to treat infection. However, higher levels of antibiotic may also increase your risk for adverse effects such as stomach upset, diarrhea, fever, loss of appetite, nausea/vomiting or rash.

What you should do about this interaction:

Make sure your healthcare professional (e.g. doctor or pharmacist) knows which medicines you are currently taking and about any kidney problems you may have.These medicines are sometimes given together for increased effectiveness of the antibiotic. Contact your doctor if you notice any side effects from the antibiotic including stomach upset, diarrhea, loss of appetite, fever, nausea, vomiting or rash. The antibiotic or the dose of the antibiotic may need to be changed.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Hoffstedt B, Haidl S, Walder M. Influence of probenecid on serum and subcutaneous tissue fluid concentrations of benzylpenicillin and ceftazidime in human volunteers. Eur J Clin Microbiol 1983 Dec;2(6):604-6.
  • 2.Stoeckel K, Trueb V, Dubach UC, McNamara PJ. Effect of probenecid on the elimination and protein binding of ceftriaxone. Eur J Clin Pharmacol 1988; 34(2):151-6.
  • 3.Gibaldi M, Schwartz MA. Apparent effect of probenecid on the distribution of penicillins in man. Clin Pharmacol Ther 1968 May-Jun;9(3):345-9.
  • 4.Brown GR. Cephalosporin-probenecid drug interactions. Clin Pharmacokinet 1993 Apr;24(4):289-300.
  • 5.Welling PG, Dean S, Selen A, Kendall MJ, Wise R. Probenecid: an unexplained effect on cephalosporin pharmacology. Br J Clin Pharmacol 1979 Nov;8(5):491-5.
  • 6.Tuano SB, Brodie JL, Kirby WM. Cephaloridine versus cephalothin: relation of the kidney to blood level differences after parenteral administration. Antimicrobial Agents Chemother 1966;6:101-6.
  • 7.Kaplan K, Reisberg BE, Weinstein L. Cephaloridine: antimicrobial activity and pharmacologic behavior. Am J Med Sci 1967 Jun;253(6):667-74.
  • 8.Kump J, Moskowitz J, Ehrenkranz NJ, Panunzio Y. Cephaloridine in the treatment of streptococcal endocarditis: a preliminary evaluation. South Med J 1969 Apr;62(4):461-4.
  • 9.Duncan WC. Treatment of gonorrhea with cefazolin plus probenecid. J Infect Dis 1974 Oct;130(4):398-401.
  • 10.Spina SP, Dillon EC Jr. Effect of chronic probenecid therapy on cefazolin serum concentrations. Ann Pharmacother 2003 May;37(5):621-4.
  • 11.Brown G, Zemcov SJ, Clarke AM. Effect of probenecid on cefazolin serum concentrations. J Antimicrob Chemother 1993 Jun;31(6):1009-11.
  • 12.Westenfelder SR, Naber KG, Madsen PO. Pharmacokinetics of a new cephalosporin, cephacetrile, in patients with normal and impaired renal function. Arzneimittelforschung 1974 Sep;24(9b):1481-5.
  • 13.Wise R, Reeves DS. Pharmacological studies on cephacetrile in human volunteers. Curr Med Res Opin 1974;2(5):249-55.
  • 14.Pitt J, Siasoco R, Kaplan K, Weinstein L. Antimicrobial activity and pharmacological behavior of cephaloglycine. Antimicrobial Agents Chemother 1967;7:630-5.
  • 15.Applestein JM, Crosby EB, Johnson WD, Kaye D. In vitro antimicrobial activity and human pharmacology of cephaloglycin. Appl Microbiol 1968 Jul;16(7):1006-10.
  • 16.Thornhill TS, Levison ME, Johnson WD, Kaye D. In vitro antimicrobial activity and human pharmacology of cephalexin, a new orally absorbed cephalosporin C antibiotic. Appl Microbiol 1969 Mar;17(3):457-61.
  • 17.Meyers BR, Kaplan K, Weinstein L. Cephalexin: microbiological effects and pharmacologic parameters in man. Clin Pharmacol Ther 1969 Nov-Dec; 10(6):810-6.
  • 18.Taylor WA, Holloway WJ. Cephalexin in the treatment of gonorrhea. Int J Clin Pharmacol 1972 Apr;6(1):7-9.
  • 19.Sales JE, Sutcliffe M, O'Grady F. Cephalexin levels in human bile in presence of biliary tract disease. Br Med J 1972 Aug 19;3(824):441-3.
  • 20.Regamey C, Libke RD, Clarke JT, Kirby WM. Pharmacokinetics of parenteral sodium cephalexin in comparison with cephalothin and cefazolin. Infection 1974;2(3):132-6.
  • 21.Oller LZ, Smith HG, Marshall MJ. Cephaloridine and cephalexin in venereological practice. Postgrad Med J 1970 Oct;Suppl:99-102.
  • 22.Mischler TW, Sugerman AA, Willard DA, Brannick LJ, Neiss ES. Influence of probenecid and food on the bioavailability of cephradine in normal male subjects. J Clin Pharmacol 1974 Nov-Dec;14(11-12):604-11.
  • 23.Roberts DH, Kendall MJ, Jack DB, Welling PG. Pharmacokinetics of cephradine given intravenously with and without probenecid. Br J Clin Pharmacol 1981 Jun;11(6):561-4.
  • 24.Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP. The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers. Br J Clin Pharmacol 1981 Apr; 11(4):353-9.
  • 25.Goodwin CS, Raftery EB, Goldberg AD, Skeggs H, Till AE, Martin CM. Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. Antimicrob Agents Chemother 1974 Sep; 6(3):338-46.
  • 26.Bint AJ, Reeves DS, Holt HA. Effect of probenecid on serum cefoxitin concentrations. J Antimicrob Chemother 1977 Nov;3(6):627-8.
  • 27.Arvidsson A, Borga O, Kager L, Pieper R. Renal elimination of cefoxitin and effect of probenecid after single and repeated doses. J Antimicrob Chemother 1981 Apr;7(4):423-30.
  • 28.Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB. Effect of orally administered probenecid on the pharmacokinetics of cefoxitin. Antimicrob Agents Chemother 1980 May;17(5):847-55.
  • 29.Marino EL, Dominguez-Gil A. The pharmacokinetics of cefadroxil associated with probenecid. Int J Clin Pharmacol Ther Toxicol 1981 Nov;19(11):506-8.
  • 30.Griffith RS, Black HR, Brier GL, Wolny JD. Effect of probenecid on the blood levels and urinary excretion of cefamandole. Antimicrob Agents Chemother 1977 May;11(5):809-12.
  • 31.LeBel M, Paone RP, Lewis GP. Effect of probenecid on the pharmacokinetics of ceftizoxime. J Antimicrob Chemother 1983 Aug;12(2):147-55.
  • 32.Adam D, Timmler R. Pharmacokinetics of ceftizoxime with and without probenecid. Arzneimittelforschung 1982;32(4):416-9.
  • 33.Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD. Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels. J Antimicrob Chemother 1997 Dec;40(6):903-6.
  • 34.Verhagen CA, Mattie H, Van Strijen E. The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion. Br J Clin Pharmacol 1994 Feb;37(2):193-7.
  • 35.Shukla UA, Pittman KA, Barbhaiya RH. Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. J Clin Pharmacol 1992 Aug;32(8):725-31.
  • 36.Pitkin D, Dubb J, Actor P, Alexander F, Ehrlich S, Familiar R, Stote R. Kinetics and renal handling of cefonicid. Clin Pharmacol Ther 1981 Nov; 30(5):587-93.
  • 37.Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ. Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. Antimicrob Agents Chemother 1989 Mar;33(3):356-61.
  • 38.Sennello LT, Quinn D, Rollins DE, Tolman KG, Sonders RC. Effect of probenecid on the pharmacokinetics of cefmenoxime. Antimicrob Agents Chemother 1983 Jun;23(6):803-7.
  • 39.Spectracef (cefditoren pivoxil) US prescribing information. Cornerstone BioPharma, Inc. July, 2008.
  • 40.Shimada J, Ueda Y. Moxalactam--absorption, excretion, distribution, and metabolism. Rev Infect Dis 1982 Nov-Dec;4 Suppl:S569-80.
  • 41.DeSante KA, Israel KS, Brier GL, Wolny JD, Hatcher BL. Effect of probenecid on the pharmacokinetics of moxalactam. Antimicrob Agents Chemother 1982 Jan;21(1):58-61.
  • 42.Jovanovich JF, Saravolatz LD, Burch K, Pohlod DJ. Failure of probenecid to alter the pharmacokinetics of ceforanide. Antimicrob Agents Chemother 1981 Oct;20(4):530-2.
  • 43.Fortaz (ceftazidime) US prescribing information. GlaxoSmithKline February, 2020.
  • 44.Penicillin G Potassium US prescribing information. Sandoz Inc. June, 2012.
  • 45.Augmentin (amoxicillin and clavulanate potassium) US prescribing information. Dr. Reddy's Laboratories Inc May, 2013.
  • 46.Tanizaki R, Nishijima T, Aoki T, Teruya K, Kikuchi Y, Oka S, Gatanaga H. High-Dose Oral Amoxicillin Plus Probenecid Is Highly Effective for Syphilis in Patients With HIV Infection. Clin Infect Dis 2015 Jul 15; 61(2):177-83.
  • 47.Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015 Jun 5;64(RR-03):1-137.
  • 48.Probenecid US prescribing information. Marlex Pharmaceuticals Inc. July, 2012.
  • 49.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
  • 50.Zosyn (piperacillin and tazobactam) US prescribing information. Wyeth Pharmaceuticals July, 2021.
  • 51.Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ, Verbist L. Piperacillin: Human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother 1978;14(6):829-37.
  • 52.Komuro M, Maeda T, Kakuo H, Matsushita H, Shimada J. Inhibition of the renal excretion of tazobactam by piperacillin. J Antimicrob Chemother 1994 Oct;34(4):555-64.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.